Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
Rapport Therapeutics (NASDAQ:RAPP), a clinical-stage biotech company focused on developing precision medicines for neurological and psychiatric disorders, has scheduled a conference call and webcast for September 8, 2025, at 8:00 am ET. The company will present topline results from its Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.
Investors can access the call through a webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations using conference ID 4762775. A replay will be available on the company's website for 90 days after the call.
Rapport Therapeutics (NASDAQ:RAPP), biotech in fase clinica specializzata nello sviluppo di terapie mirate per disturbi neurologici e psichiatrici, ha programmato una conference call e webcast per il 8 settembre 2025 alle 8:00 ET. La società presenterà i risultati principali del trial di Fase 2a su RAP-219 in pazienti con crisi focali resistenti ai farmaci.
Gli investitori potranno seguire la call tramite il link webcast o chiamando il (800) 715-9871 negli USA o il (646) 307-1963 da altre località, utilizzando l'ID conferenza 4762775. Una registrazione sarà disponibile sul sito della società per 90 giorni dopo la chiamata.
Rapport Therapeutics (NASDAQ:RAPP), una biotecnológica en fase clínica centrada en desarrollar medicamentos de precisión para trastornos neurológicos y psiquiátricos, ha programado una conferencia telefónica y webcast para el 8 de septiembre de 2025 a las 8:00 ET. La compañía presentará los resultados principales de su ensayo de fase 2a de RAP-219 en pacientes con crisis focales resistentes a los medicamentos.
Los inversores pueden acceder a la llamada mediante el enlace del webcast o llamando al (800) 715-9871 en EE. UU. o al (646) 307-1963 desde otras ubicaciones, usando el ID de conferencia 4762775. Una grabación estará disponible en la web de la compañía durante 90 días después de la llamada.
Rapport Therapeutics (NASDAQ:RAPP)는 신경계 및 정신 질환에 대한 정밀 의약품 개발에 주력하는 임상 단계 바이오텍으로, 2025년 9월 8일 오전 8:00 ET에 컨퍼런스 콜 및 웹캐스트를 예정했습니다. 회사는 약물에 내성인 국소 발작 환자를 대상으로 한 RAP-219의 2a상 시험의 주요 결과를 발표할 예정입니다.
투자자는 웹캐스트 링크를 통해 접속하거나 미국 내에서는 (800) 715-9871, 기타 지역에서는 (646) 307-1963으로 전화해 회의 ID 4762775를 사용하면 참여할 수 있습니다. 콜 이후 90일간 회사 웹사이트에서 재청취가 가능합니다.
Rapport Therapeutics (NASDAQ:RAPP), une société biotechnologique en phase clinique axée sur le développement de médicaments de précision pour les troubles neurologiques et psychiatriques, a programmé une conférence téléphonique et un webdiffusion pour le 8 septembre 2025 à 8h00 ET. La société présentera les résultats principaux de son essai de phase 2a de RAP-219 chez des patients présentant des crises focales résistantes aux médicaments.
Les investisseurs peuvent accéder à l'appel via le lien du webcast ou en composant le (800) 715-9871 aux États-Unis ou le (646) 307-1963 depuis d'autres lieux en utilisant l'ID de conférence 4762775. Une rediffusion sera disponible sur le site de la société pendant 90 jours après l'appel.
Rapport Therapeutics (NASDAQ:RAPP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung präziser Therapien für neurologische und psychiatrische Erkrankungen konzentriert, hat eine Telefonkonferenz und ein Webcast für den 8. September 2025 um 8:00 Uhr ET angesetzt. Das Unternehmen wird die Hauptergebnisse der Phase‑2a‑Studie von RAP‑219 bei Patientinnen und Patienten mit medikamentenresistenten fokalen Anfällen vorstellen.
Investoren können dem Call über den Webcast‑Link folgen oder in den USA unter (800) 715-9871 bzw. unter (646) 307-1963 aus anderen Regionen anrufen und die Konferenz‑ID 4762775 verwenden. Eine Aufzeichnung wird für 90 Tage nach dem Call auf der Website des Unternehmens verfügbar sein.
- None.
- None.
BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.
Individuals interested in listening to the live conference call may do so through this webcast link or by dialing (800) 715-9871 in the U.S. or (646) 307-1963 for other locations and reference conference ID 4762775. A webcast replay will be available from the “Investors” section of the Company’s website here for 90 days following the completion of the call.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological or psychiatric disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently pursuing RAP-219 as a potential treatment for drug-resistant focal onset seizures, bipolar mania and diabetic peripheral neuropathic pain. Additional preclinical and late-stage discovery stage programs are also underway, including targeting chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
When will Rapport Therapeutics (RAPP) announce Phase 2a results for RAP-219?
What is the purpose of Rapport Therapeutics' RAP-219 clinical trial?
How can investors access Rapport Therapeutics' (RAPP) Phase 2a results conference call?
Where can I find the replay of Rapport Therapeutics' Phase 2a results presentation?
